After having already provided a first indication of the current business year in March, the Executive Board is now further refining its forecast for 2012. In general, the guidance for the Group reflects the modest recovery rate of the global economy.
| XLS |
|
Merck Guidance for 2012 | |||
|
|
| ||
|
|
| ||
|
Merck Divsions |
Sales Growth | ||
| |||
|
Merck Serono |
+ ~ 2% | ||
|
Consumer Health |
+0% – 2% | ||
|
Performance Materials |
+2% – 3% | ||
|
Merck Millipore |
+4% – 6% | ||
|
|
| ||
|
Merck Group |
| ||
|
Total Revenues |
~ € 10.5 bn | ||
|
EBITDA pre one-time items* |
€ 2.8 bn – € 2.9 bn | ||
Division Profitability Expectations
- Merck Serono: Modest increase before efficiency savings
- Consumer Health: Slight improvement in a moderate market environment
- Performance Materials: Close to 2011 level
- Merck Millipore: Improving in line with sales growth
The net financial debt of the Merck Group resulting from the 2010 acquisition of Millipore continues to decrease at an excellent pace.